Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 286

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome

Open access
De Leo, Vincenzo, la Marca, Antonio, Petraglia, Felice·2003·Endocrine Reviews

Abstract

Polycystic ovary syndrome (PCOS) is a medical condition that has brought multiple specialists together.Gynecologists, endocrinologists, cardiologists, pediatricians, and dermatologists are all concerned with PCOS patients and share research data and design clinical trials to learn more about the syndrome.Insulin resistance is a common feature of PCOS and is more marked in obese women, suggesting that PCOS and obesity have a synergistic effect on the magnitude of the insulin disorder.Hyperinsulinemia associated with insulin resistance has been causally linked to all features of the syndrome, such as hyperandrogenism, reproductive disorders, acne, hirsutism, and meta-bolic disturbances.Women with PCOS should be evaluated for cardiovascular risk factors, such as lipid profile and blood pressure.Modification of diet and lifestyle should be suggested to those who are obese.Several insulin-lowering agents have been tested in the management of PCOS.In particular, metformin is the only drug currently in widespread clinical use for treatment of PCOS.In a high percentage of patients, treatment with metformin is followed by regularization of menstrual cycle, reduction in hyperandrogenism and in cardiovascular risk factors, and improvement in response to therapies for induction of ovulation.(Endocrine Reviews 24: 633-667, 2003) I. Introduction II.Definition of PCOS A. Endocrine profile B. Reproductive abnormalities C. Long-term health consequences D. Summary III.Insulin Resistance in PCOS A. Definition and prevalence B. Diagnosis C. Pathogenesis of insulin resistance D. Summary IV.Insulin-Lowering Strategies A. Metformin B. Thiazolidinediones C. Other drugs D. Weight loss E. Summary and clinical recommendations V.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/er.2002-0015

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 50 references

Cited by

See all 286

Metadata

Authors
De Leo, V., la Marca, A., & Petraglia, F.
Venue
Endocrine Reviews
Published
2003-10-01
Volume
24
Issue
5
Pages
633-667
ISSN
  • 0163-769X (ISSN-L)
  • 1945-7189
OpenAlex
W2119823280
Cited by
286
References
50
FWCI
17.13
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome. https://app.cochat.ai/papers/10.1210/er.2002-0015
The paper
De Leo, V., la Marca, A., & Petraglia, F. (2003). Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome. Endocrine Reviews. https://doi.org/10.1210/er.2002-0015

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.